Health Care & Life Sciences » Biotechnology | e-Therapeutics PLC

e-Therapeutics PLC | Balance Sheet

Fiscal year is February-January. All values GBP Thousands.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
43,147.00
33,822.00
24,842.00
13,975.00
9,597.00
5,904
Total Accounts Receivable
1,266.00
2,298.00
3,023.00
3,248.00
1,455.00
1,116
Other Current Assets
591.00
1,304.00
918.00
501.00
504.00
328
Total Current Assets
45,004.00
37,424.00
28,783.00
17,724.00
11,556.00
7,348
Net Property, Plant & Equipment
121.00
96.00
64.00
51.00
71.00
42
Intangible Assets
496.00
637.00
740.00
156.00
135.00
119
Total Assets
45,621.00
38,157.00
29,587.00
17,931.00
11,762.00
7,509
Accounts Payable
402.00
601.00
-
-
-
Other Current Liabilities
601.00
532.00
1,156.00
1,951.00
1,024.00
Total Current Liabilities
1,003.00
1,133.00
1,156.00
1,951.00
1,024.00
Total Liabilities
1,003.00
1,133.00
1,156.00
1,951.00
1,024.00
Common Equity (Total)
44,618.00
37,024.00
28,431.00
15,980.00
10,738.00
Total Shareholders' Equity
44,618.00
37,024.00
28,431.00
15,980.00
10,738.00
Total Equity
44,618.00
37,024.00
28,431.00
15,980.00
10,738.00
Liabilities & Shareholders' Equity
45,621.00
38,157.00
29,587.00
17,931.00
11,762.00

About e-Therapeutics

View Profile
Address
17 Blenheim Office Park
Long Hanborough Oxfordshire OX29 8LN
United Kingdom
Employees -
Website http://etherapeutics.co.uk
Updated 07/08/2019
e-Therapeutics Plc is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. It focuses on the therapeutic immune-oncology, addressing drug resistance in targeted cancer therapies and antivirals. It offers the following variety of preclinical stage assets: ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFa; ETS2400, Hedgehog pathway inhibition; and ETS5200, broad spectrum antivirals together with two immuno-oncology checkpoint projects.